Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 448

1.

Molecular mechanisms of Carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of Metformin.

Efentakis P, Kremastiotis G, Varela A, Nikolaou PE, Papanagnou ED, Davos CH, Tsoumani M, Agrogiannis G, Konstantinidou A, Kastritis E, Kanaki Z, Iliodromitis EK, Klinakis A, Dimopoulos MA, Trougakos IP, Andreadou I, Terpos E.

Blood. 2018 Nov 27. pii: blood-2018-06-858415. doi: 10.1182/blood-2018-06-858415. [Epub ahead of print]

PMID:
30482794
2.

Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.

Polyzos SA, Kountouras J, Anastasilakis AD, Makras P, Hawa G, Sonnleitner L, Missbichler A, Doulberis M, Katsinelos P, Terpos E.

Hormones (Athens). 2018 Nov 22. doi: 10.1007/s42000-018-0083-8. [Epub ahead of print]

PMID:
30467685
3.

IMiDs for myeloma induced renal impairment.

Gavriatopoulou M, Terpos E, Dimopoulos MA.

Oncotarget. 2018 Oct 26;9(84):35476-35477. doi: 10.18632/oncotarget.26270. eCollection 2018 Oct 26. No abstract available.

4.

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.

Fotiou D, Sergentanis TN, Papageorgiou L, Stamatelopoulos K, Gavriatopoulou M, Kastritis E, Psaltopoulou T, Salta S, Van Dreden P, Sangare R, Larsen AK, Terpos E, Elalamy I, Dimopoulos MA, Gerotziafas GT.

Blood Cancer J. 2018 Nov 7;8(11):102. doi: 10.1038/s41408-018-0135-y.

5.

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.

Voskaridou E, Ntanasis-Stathopoulos I, Papaefstathiou A, Christoulas D, Dimopoulou M, Repa K, Papatheodorou A, Peppa M, Terpos E.

Blood Adv. 2018 Nov 13;2(21):2837-2847. doi: 10.1182/bloodadvances.2018023085.

6.

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group.

Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, Lentzsch S, Moreau P, Cavo M, Miguel JS, Dimopoulos MA, Rajkumar SV, Durie BGM, Terpos E, Delorme S.

Blood Cancer J. 2018 Oct 4;8(10):95. doi: 10.1038/s41408-018-0124-1.

7.

Management of multiple myeloma bone disease: impact of treatment on renal function.

Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA.

Expert Rev Hematol. 2018 Nov;11(11):881-888. doi: 10.1080/17474086.2018.1531702. Epub 2018 Oct 20.

PMID:
30285492
8.

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.

Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Papasotiriou I, Fotiou D, Migkou M, Roussou M, Kanellias N, Ziogas D, Dialoupi I, Eleutherakis Papaiakovou E, Kastritis E, Dimopoulos MA.

Clin Lymphoma Myeloma Leuk. 2018 Aug 23. pii: S2152-2650(18)30532-9. doi: 10.1016/j.clml.2018.07.294. [Epub ahead of print]

PMID:
30224328
9.

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.

Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M.

Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31.

10.

Variation of endothelium-related hemostatic factors during sepsis.

Vasileiadis I, Politou M, Dimopoulos S, Rovina N, Kyriakopoulou M, Kyriakoudi A, Tripodaki ES, Koutsouri T, Terpos E, Koulouris N, Koutsoukou A.

Microcirculation. 2018 Nov;25(8):e12500. doi: 10.1111/micc.12500. Epub 2018 Oct 10.

PMID:
30159948
11.

GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.

Schmidts A, Grünewald J, Kleber M, Terpos E, Ihorst G, Reinhardt H, Walz G, Wäsch R, Engelhardt M, Zschiedrich S.

Clin Exp Nephrol. 2018 Aug 20. doi: 10.1007/s10157-018-1626-7. [Epub ahead of print]

PMID:
30128942
12.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

PMID:
30098165
13.

Role of the RANK/RANKL Pathway in Multiple Myeloma.

Raje NS, Bhatta S, Terpos E.

Clin Cancer Res. 2018 Aug 9. doi: 10.1158/1078-0432.CCR-18-1537. [Epub ahead of print] Review.

PMID:
30093448
14.

Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis.

Polyzos SA, Terpos E.

Endocrine. 2018 Nov;62(2):487-489. doi: 10.1007/s12020-018-1699-9. Epub 2018 Aug 3. No abstract available.

PMID:
30074171
15.

Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).

Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M; European Hematology Association, the European Myeloma Network and the Italian Society of Arterial Hypertension.

Haematologica. 2018 Sep;103(9):1422-1432. doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26. Review.

16.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Review.

PMID:
30038381
17.

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25.

18.

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.

Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, Dimopoulos MA.

Eur J Haematol. 2018 Oct;101(4):556-565. doi: 10.1111/ejh.13147. Epub 2018 Sep 5.

PMID:
30027641
19.

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.

Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, Mavrianou-Koutsoukou N, Liacos C, Patseas D, Kanellias N, Migkou M, Ziogas DC, Eleutherakis-Papaiakovou E, Roussou M, Fotiou D, Terpos E, Kastritis E, Dimopoulos MA.

Leukemia. 2018 Dec;32(12):2617-2625. doi: 10.1038/s41375-018-0197-7. Epub 2018 Jul 19.

20.

Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8.

PMID:
29943159
21.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25. Review.

22.

The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis.

Tsartsalis AN, Lambrou GI, Tsartsalis D, Savvidis C, Karantza M, Terpos E, Kanaka-Gantenbein C, Chrousos GP, Kattamis A.

Hormones (Athens). 2018 Jun;17(2):153-166. doi: 10.1007/s42000-018-0019-3. Epub 2018 May 2. Review.

PMID:
29858849
23.

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, Kanellias N, Ziogas DC, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Trougakos IP, Tsitsilonis O, Dimopoulos MA.

Blood Cancer J. 2018 May 24;8(5):46. doi: 10.1038/s41408-018-0086-3. No abstract available.

24.

Optimizing therapy in bortezomib-exposed patients with multiple myeloma.

Migkou M, Gavriatopoulou M, Terpos E, Dimopoulos MA.

Expert Rev Hematol. 2018 Jun;11(6):463-469. doi: 10.1080/17474086.2018.1479637. Epub 2018 May 28.

PMID:
29788798
25.

Going the distance: Are we losing patients along the multiple myeloma treatment pathway?

Terpos E, Suzan F, Goldschmidt H.

Crit Rev Oncol Hematol. 2018 Jun;126:19-23. doi: 10.1016/j.critrevonc.2018.03.021. Epub 2018 Mar 29. Review.

26.

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13. Erratum in: Ann Hematol. 2018 Jun 26;:.

27.

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.

Terpos E, Ntanasis-Stathopoulos I, Christoulas D, Bagratuni T, Bakogeorgos M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Dimopoulos MA.

Blood Cancer J. 2018 May 11;8(5):42. doi: 10.1038/s41408-018-0075-6.

28.

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.

Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A.

Leuk Lymphoma. 2018 May 9:1-9. doi: 10.1080/10428194.2018.1459609. [Epub ahead of print]

PMID:
29741423
29.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

30.

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.

Papanagnou ED, Terpos E, Kastritis E, Papassideri IS, Tsitsilonis OE, Dimopoulos MA, Trougakos IP.

Oncotarget. 2018 Apr 3;9(25):17797-17809. doi: 10.18632/oncotarget.24882. eCollection 2018 Apr 3.

31.

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.

Eleutherakis-Papaiakovou E, Kastritis E, Gavriatopoulou M, Christoulas D, Roussou M, Ntanasis-Stathopoulos I, Kanellias N, Papatheodorou A, Dimopoulos MA, Terpos E.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):431-437. doi: 10.1016/j.clml.2018.03.010. Epub 2018 Mar 31.

PMID:
29685422
32.

Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study.

von Moos R, Body JJ, Guenther O, Terpos E, Acklin YP, Finek J, Pereira J, Maniadakis N, Hechmati G, Talbot S, Sleeboom H.

J Bone Oncol. 2018 Feb 5;10:49-56. doi: 10.1016/j.jbo.2018.01.003. eCollection 2018 Mar.

33.

Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.

Terpos E; International Myeloma Society.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):321-334. doi: 10.1016/j.clml.2018.02.015. Epub 2018 Mar 1. Review.

PMID:
29576386
34.

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.

Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Vadikolia C, Michael M, Kalpadakis C, Gougopoulou T, Prokopiou C, Kaiafa G, Christoulas D, Gavriatopoulou M, Giannopoulou E, Labropoulou V, Verrou E, Kastritis E, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.

Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6.

35.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.

Raje N, Roodman GD, Willenbacher W, Shimizu K, García-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G.

J Med Econ. 2018 May;21(5):525-536. doi: 10.1080/13696998.2018.1445634. Epub 2018 Mar 5.

PMID:
29480139
36.

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD.

Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.

PMID:
29429912
37.

The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.

Cavo M, Terpos E, Bargay J, Einsele H, Cavet J, Greil R, de Wit E.

Expert Rev Hematol. 2018 Mar;11(3):219-237. doi: 10.1080/17474086.2018.1437345. Epub 2018 Feb 16.

PMID:
29415570
38.

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.

Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G.

Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31.

PMID:
29386197
39.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L.

J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1. Review.

40.

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA.

Blood Cancer J. 2018 Jan 12;8(1):7. doi: 10.1038/s41408-017-0037-4. Review.

41.

Cardiac and renal complications of carfilzomib in patients with multiple myeloma.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E.

Blood Adv. 2017 Feb 27;1(7):449-454. doi: 10.1182/bloodadvances.2016003269. eCollection 2017 Feb 28.

42.

Re: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report.

Tournis S, Michopoulos S, Makris K, Terpos E.

J Bone Miner Res. 2018 Mar;33(3):543-545. doi: 10.1002/jbmr.3372. Epub 2018 Feb 2. No abstract available.

PMID:
29281128
43.

Periostin and sclerostin levels in juvenile Paget's disease.

Polyzos SA, Makras P, Anastasilakis AD, Mintziori G, Kita M, Papatheodorou A, Kokkoris P, Terpos E.

Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):269-271. doi: 10.11138/ccmbm/2017.14.2.269. Epub 2017 Oct 25.

44.

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.

Tsakiri EN, Terpos E, Papanagnou ED, Kastritis E, Brieudes V, Halabalaki M, Bagratuni T, Florea BI, Overkleeft HS, Scorrano L, Skaltsounis AL, Dimopoulos MA, Trougakos IP.

Sci Rep. 2017 Dec 19;7(1):17802. doi: 10.1038/s41598-017-17596-4.

45.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

46.

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P.

Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7. Review.

47.

Rare manifestations of extramedullary myeloma: testicular plasmacytomas.

Ntanasis-Stathopoulos I, Gavriatopoulou M, Eleftherakis-Papaiakovou E, Kastritis E, Terpos E, Dimopoulos MA.

Leuk Lymphoma. 2018 Aug;59(8):2002-2004. doi: 10.1080/10428194.2017.1410887. Epub 2017 Dec 7. No abstract available.

PMID:
29214871
48.

The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.

Anagnostis P, Vakalopoulou S, Christoulas D, Paschou SA, Papatheodorou A, Garipidou V, Kokkoris P, Terpos E.

Haemophilia. 2018 Mar;24(2):316-322. doi: 10.1111/hae.13384. Epub 2017 Dec 1.

PMID:
29194852
49.

Biology and treatment of myeloma related bone disease.

Terpos E, Christoulas D, Gavriatopoulou M.

Metabolism. 2018 Mar;80:80-90. doi: 10.1016/j.metabol.2017.11.012. Epub 2017 Nov 23. Review.

PMID:
29175022
50.

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.

Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Roussou M, Migkou M, Ziogas DC, Kanellias N, Terpos E, Dimopoulos MA.

Blood. 2018 Jan 25;131(4):464-467. doi: 10.1182/blood-2017-10-809293. Epub 2017 Nov 22. No abstract available.

PMID:
29167176

Supplemental Content

Loading ...
Support Center